Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + liposomal irinotecan + 5-fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a quadruple drug combination regimen used in oncology clinical trials, specifically as a second-line therapy for advanced biliary tract cancers. - **Nivolumab** is a monoclonal antibody checkpoint inhibitor targeting PD-1, enhancing antitumor immune response. - **Liposomal irinotecan** is a nanoparticle-formulated topoisomerase I inhibitor that delivers chemotherapy more effectively and with altered toxicity. - **5-fluorouracil** is a pyrimidine analog antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis in cancer cells. - **Leucovorin** is a folate analog that potentiates the activity of 5-fluorouracil by stabilizing its ternary complex with thymidylate synthase. The regimen is mainly investigated for patients with unresectable or metastatic biliary tract cancer who have progressed after platinum-based chemotherapy. Clinical trials report modest efficacy and tolerability, but the combination may prolong progression-free and overall survival in a subset of patients[1][3].
- Brand names
- Opdivo (for nivolumab)Onivyde (for nal-irinotecan)
- Other names
- nivolumab + liposomal irinotecan + 5-fluorouracil + leucovorin
02
Targets
TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on nivolumab + liposomal irinotecan + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + liposomal irinotecan + 5-fluorouracil + leucovorin.